Viewing data from:

ZOMIG

NDA

ZOLMITRIPTAN | N020768 | IPR PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Zolmitriptan* (2023)

Total Spending

$8.2M

Total Claims

43,437

Beneficiaries

11,158

Avg Cost/Unit

$17.17

Spending Trend

$1.0M(2019)→$8.7M(2019)→$5.1M(2019)→$9.5M(2020)→$1.3M(2020)→$4.9M(2020)→$1.4M(2021)→$6.8M(2021)→$6.4M(2021)→$3.0M(2022)→$1.7M(2022)→$9.0M(2022)→$1.3M(2023)→$1.3M(2023)→$8.2M(2023)

YoY Change:-9.1%

5yr CAGR:+16.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain17 active DMFs3 inactive

17 active API suppliers hold Drug Master Files for this ingredient.

SMS PHARMACEUTICALS LTDZOLMITRIPTAN

DMF 201102007

MATRIX PHARMACORP PRIVATE LTDZOLMITRIPTAN USP

DMF 206392007

NATCO PHARMA LTDZOLMITRIPTAN

DMF 213082008

TAPI NL BVZOLMITRIPTAN

DMF 222052008

ALIVUS LIFE SCIENCES LTDZOLMITRIPTAN USP

DMF 222372008

SUVEN LIFE SCIENCES LTDZOLMITRIPTAN

DMF 232072009

JUBILANT BIOSYS LTDZOLMITRIPTAN USP

DMF 236272010

INKE SAZOLMITRIPTAN

DMF 246492011

MACLEODS PHARMACEUTICALS LTDZOLMITRIPTAN

DMF 248692011

SUN PHARMACEUTICAL INDUSTRIES LTDZOLMITRIPTAN

DMF 250782011

ORBION PHARMACEUTICALS PRIVATE LTDZOLMITRIPTAN

DMF 252362011

HETERO DRUGS LTDZOLMITRIPTAN

DMF 252972011

ALEMBIC PHARMACEUTICALS LTDZOLMITRIPTAN USP

DMF 255032011

DR REDDYS LABORATORIES LTDZOLMITRIPTAN (PROCESS-II)

DMF 257342012

EMCURE PHARMACEUTICALS LTDZOLMITRIPTAN

DMF 261052012

APITORIA PHARMA PRIVATE LTDZOLMITRIPTAN

DMF 275022013

SYN-TECH CHEM AND PHARM CO LTDZOLMITRIPTAN

DMF 278182013

DR REDDYS LABORATORIES LTDInactiveZOLMITRIPTAN

DMF 201942007

APOTEX PHARMACHEM INDIA PVT LTDInactiveZOLMITRIPTAN

DMF 238962010

UNICHEM LABORATORIES LTDInactiveZOLMITRIPTAN USP

DMF 247562011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

9 letters from Drugs@FDA

Date	Submission	Document
Dec 31, 2018	SUPPL -23	View Letter (PDF)
Sep 18, 2012	SUPPL -21	View Letter (PDF)
Sep 18, 2012	SUPPL -19	View Letter (PDF)
Aug 16, 2010	SUPPL -17	View Letter (PDF)
Nov 19, 2004	SUPPL -12	View Letter (PDF)
Jan 14, 2004	SUPPL -13	View Letter (PDF)
Jun 8, 2003	SUPPL -11	View Letter (PDF)
Oct 9, 2002	SUPPL -10	View Letter (PDF)
Jan 29, 2002	SUPPL -6	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Nov 25, 1997

No patent or exclusivity listings for this strength.

#002 — 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Nov 25, 1997